News UK must draw up post-Brexit pharma strategy Big pharma could take its money elsewhere post Brexit, report warns.
News Fine pharma for price gouging, says Clinton Hillary Clinton wants to fine companies for gouging prices of generics.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.